Современная ревматология (Oct 2019)

Experience with methotrexate in a patient with calcium pyrophosphate crystal deposition disease

  • E. V. Ilyinykh,
  • M. S. Eliseev

DOI
https://doi.org/10.14412/1996-7012-2019-4-96-98
Journal volume & issue
Vol. 13, no. 4
pp. 96 – 98

Abstract

Read online

The paper discusses the results of using methotrexate (MTX) in real clinical practice in a patient with calcium pyrophosphate crystal deposition resistant to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs, and hydroxychloroquine) It demonstrates the efficiency and possibility of safely using MTX at a dose of 20 mg/week during a year.

Keywords